Tuberculosis

Whole Genome Sequencing Use in Predicting TB Resistance

By

Benjamin Patterson

Publish Date December 25, 2018

Whole genome sequencing of M tuberculosis isolates can identify complete drug susceptibility profiles, allowing precise treatment in early TB infection.

Could a New Universal Tuberculosis Regimen Help End the TB Pandemic?

By

Benjamin Patterson

Publish Date May 31, 2018

The Lancet Respiratory Medicine staged a debate between proponents and opponents of pan-TB regimens to tackle the current suboptimal worldwide management of TB resistance.

Latent Tuberculosis Testing and Treatment Recommendations

By

Tori Rodriguez, MA, LPC, AHC

Publish Date December 7, 2017

Recommendations for testing and treating latent TB infection have been discussed by a representative from the California Department of Public Health.

QuantiFERON-TB Gold Plus Comparable to Other Assays for Incident Tuberculosis

By

Bryant Moeller

QuantiFERON-TB Gold Plus was comparable to other interferon gamma release assays for predicting tuberculosis in adults with recent contacts.

Incidence of Tuberculosis High in Children Exposed to the Disease

Preventive therapy was effective in most children with tuberculosis if given before development of active disease.

Updated Guidelines for Latent TB Infection Treatment Released by CDC and NTCA

By

Brandon May

The National Tuberculosis Controllers Association and the Centers for Disease Control and Prevention have released updated guidelines for the treatment of latent tuberculosis infection.

Normal Dose Moxifloxacin Maintained Effectiveness in Rifampin-Resistant TB

By

Sheila Jacobs

A short, 9-month regimen of normal dose moxifloxacin maintained good effectiveness up to 24 months after therapy cessation in patients with rifampicin-resistant tuberculosis.

Early Bactericidal Activity of High-Dose Isoniazid for Drug Resistant TB

By

Bradley van Paridon

Daily doses of 10 to 15 mg/kg isoniazid demonstrated similar activity against tuberculosis (TB) strains with inhA mutations as 5 mg/kg doses against drug-sensitive strains.

Rifampicin May Be Safer Than Isoniazid in Latent Tuberculosis Treatment

By

Zahra Masoud

In patients without a contraindication, rifampicin may be the safest treatment option for latent tuberculosis (TB) infection.

Latent TB Infection Treatment: 4 Months of Rifampin vs 9 Months of Isoniazid

By

Pulmonology Advisor Contributing Writer

Treatment with 4 months of rifampin for latent tuberculosis infection was associated with higher adherence, lower costs, and lower risk for severe hepatoxicity compared with 9 months of isoniazid.

Post-Tuberculosis Lung Disease in HIV-Associated Tuberculosis Common

By

Virginia A. Schad, PharmD, RPh

Post-tuberculosis lung disease is common in patients with HIV-associated tuberculosis at high risk for tuberculosis-associated immune reconstitution inflammatory syndrome.